Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

Blood - Tập 100 - Trang 3869-3876 - 2002
Jeanne E. Anderson, Kenneth J. Kopecky, Cheryl L. Willman, David Head, Margaret R. O’Donnell, Frederick W. Luthardt, Thomas H. Norwood, I-Ming Chen, Stanley P. Balcerzak, David B. Johnson, Frederick R. Appelbaum

Tóm tắt

Complete remission and long-term survival rates are low for older adults treated for acute myeloid leukemia (AML). Because of favorable phase 2 data using mitoxantrone and etoposide, we conducted a phase 3 study (SWOG-9333) in which patients over 55 years of age with previously untreated AML were randomized to receive mitoxantrone (10 mg/m2 per day × 5) and etoposide (100 mg/m2per day × 5) [ME], or cytarabine (200 mg/m2 per day × 7) and daunorubicin (45 mg/m2 per day × 3) [AD] as induction therapy. The randomization was stratified by age, onset of leukemia, and multidrug resistance phenotype. Over a 4-year period, 328 eligible patients from 66 institutions were enrolled. The complete remission rate was 34% (95% confidence interval [CI] 26%-41%) for patients in the ME and 43% (CI 35%-51%) for patients in the AD treatment arm (one-tailedP value .96). The rates of resistant disease were 43% (CI 35%-51%) and 34% (CI 27%-42%), respectively, for the 2 treatment arms (one-tailed P value .95). The estimated overall survival at 2 years was 11% (CI 6%-15%) and 19% (CI 12%-25%) for patients randomized to ME and to AD induction therapy, respectively (one-tailed P value .99). After accounting for the independent prognostic factors associated with survival (karyotype, performance status, age, white blood cell count), exploratory analysis suggested there was a worse survival for patients who received ME compared with AD induction therapy (2-tailed P value .0066). We conclude that the results of our study do not demonstrate any benefit to the use of ME induction chemotherapy instead of AD in older patients with AML.

Tài liệu tham khảo

Yin, 1993, Clinical annotation. Acute myeloid leukaemia in the elderly: biology and treatment., Br J Haematol., 83, 1, 10.1111/j.1365-2141.1993.tb04622.x Wiernik, 1992, Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia., Blood., 79, 313, 10.1182/blood.V79.2.313.313 Berman, 1991, Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia., Blood., 77, 1666, 10.1182/blood.V77.8.1666.1666 Mayer, 1994, Intensive postremission chemotherapy in adults with acute myeloid leukemia., N Engl J Med., 331, 896, 10.1056/NEJM199410063311402 Bishop, 1996, A randomized study of high-dose cytarabine in induction in acute myeloid leukemia., Blood., 87, 1710, 10.1182/blood.V87.5.1710.1710 Weick, 1996, A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study., Blood., 88, 2841, 10.1182/blood.V88.8.2841.bloodjournal8882841 Cassileth, 1992, Varying intensity of postremission therapy in acute myeloid leukemia., Blood., 79, 1924, 10.1182/blood.V79.8.1924.1924 Cassileth, 1998, Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission., N Engl J Med., 339, 1649, 10.1056/NEJM199812033392301 Leith, 1999, Frequency and clinical significance of the expression of the multidrug resistance proteins MDR-1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. a Southwest Oncology Group study., Blood., 94, 1086 Leith, 1997, Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR-1) and cytogenetics distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy. a Southwest Oncology Group study., Blood., 89, 3323, 10.1182/blood.V89.9.3323 Baudard, 1994, Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients., Br J Haematol., 86, 82, 10.1111/j.1365-2141.1994.tb03256.x Leith, 1996, Acute myeloid leukemia in the elderly: high frequency of trilineage dyspoiesis suggests that elderly AML is biologically similar to AML arising secondary to myelodysplasia [abstract]., Blood., 88, 559a Latagliata, 1999, Acute myeloid leukemia in the elderly: ‘per aspera ad astra’?, Leukemia Research., 23, 603, 10.1016/S0145-2126(99)00085-5 Hiddemann, 1999, Management of acute myeloid leukemia in elderly patients., J Clin Onc., 17, 3569, 10.1200/JCO.1999.17.11.3569 Ryan, 1992, Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age: a Southwest Oncology Group study., Am J Clin Oncol., 15, 69, 10.1097/00000421-199202000-00013 Godwin, 1998, A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study., Blood., 91, 3607, 10.1182/blood.V91.10.3607 Bennett, 1997, Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience., Cancer Supplement., 80, 2205, 10.1002/(SICI)1097-0142(19971201)80:11+<2205::AID-CNCR7>3.0.CO;2-G Arlin, 1990, Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)., Leukemia., 4, 177 Yin, 1991, Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia., Br J Haematol., 79, 415, 10.1111/j.1365-2141.1991.tb08049.x Ho, 1991, Etoposide in acute leukemia: past experience and future perspectives., Cancer., 67, 281, 10.1002/1097-0142(19910101)67:1+<281::AID-CNCR2820671312>3.0.CO;2-H Bishop, 1990, Etoposide in acute nonlymphocytic leukemia., Blood., 75, 27, 10.1182/blood.V75.1.27.27 Ho, 1988, Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia—an active and well-tolerated regimen., J Clin Onc., 6, 213, 10.1200/JCO.1988.6.2.213 Knauf, 1994, Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia., Leukemia and Lymphoma., 12, 421, 10.3109/10428199409073783 Bow, 1996, Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide., J Clin Onc., 14, 1345, 10.1200/JCO.1996.14.4.1345 Cheson, 1990, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia., J Clin Onc., 8, 813, 10.1200/JCO.1990.8.5.813 Head, 1985, Institutional performance in application of the FAB classification of acute leukemia., Cancer., 55, 1979, 10.1002/1097-0142(19850501)55:9<1979::AID-CNCR2820550925>3.0.CO;2-# Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes., Br J Haematol., 51, 189, 10.1111/j.1365-2141.1982.tb08475.x Rowe, 1995, A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)., Blood., 86, 457, 10.1182/blood.V86.2.457.bloodjournal862457 Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study., Blood., 96, 4075, 10.1182/blood.V96.13.4075 Cox, 1970, Analysis of Binary Data. Cox, 1972, Regression models and life tables., J R Stat Soc., 34, 187 Kaplan, 1958, Nonparametric estimation from incomplete observations., J Am Stat Assoc., 53, 457, 10.1080/01621459.1958.10501452 Rowe, 1998, A phase III study of daunorubicin vs idarubicin vs mitroxantrone for older adult patients (> 55 years) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993) [abstract]., Blood., 92, 313a Löwenberg, 1998, Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9., J Clin Onc., 16, 872, 10.1200/JCO.1998.16.3.872 Johnson, 1993, Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival., Br J Haematol., 85, 300, 10.1111/j.1365-2141.1993.tb03170.x
Thông tin
Thông tin xuất bản

Blood

Tập 100

3869-3876

Thông tin tác giả